A review of antisense therapeutic interventions for molecular biological targets in asthma.

摘要: Modern tools of genomics and proteomics reveal potential therapeutic antisense targets in asthma, increasing the interest development anti-mRNA drugs. In allergic asthma experimental models, oligonucleotides (ASO) are administered by inhalation or systemically. ASO can be used for a large number molecular targets: cell membrane receptors (G-protein coupled receptors, cytokine chemokine receptors), proteins, ion channels, cytokines related factors, signaling non-receptor protein kinases (tyrosine kinases, serine/threonine kinases) regulators transcription belonging to Cys4 zinc finger nuclear receptor type beta-scaffold factors with minor groove contacts classes/superclasses factors. A respirable against adenosine A(1) was investigated human trials. RNase P-associated external guide sequence (EGS) delivered into pulmonary tissues represents potentially new approach as well ribozyme strategies. Small interfering RNA (siRNA) targeting key molecules involved patho-physiology expected benefit RNAi immunotherapy. Antagomirs, synthetic analogs microRNA (miRNA), have important roles regulation gene expression asthma. interference (RNAi) technologies offer higher efficiency suppressing specific genes, compared traditional approaches.